Goldman Sachs: Nvidia (NVDA.US) is one of the most important stocks globally.
Nvidia's fourth quarter financial report for fiscal year 2024, to be released after the U.S. stock market closes on Wednesday, will undoubtedly be a major factor affecting the market, to the point where Goldman Sachs' trading department referred to Nvidia as the "most important stock on Earth".
NVIDIA (NVDA.US) will undoubtedly become a major factor affecting the market as it releases its fourth quarter earnings for the fiscal year 2024 after the US stock market closes on Wednesday. NVIDIA has been referred to as the "most important stock on earth" by Goldman Sachs trading department due to its significant weight in various indexes and the large number of long positions in the stock. The options positions on the stock suggest that its price could fluctuate by about 11% in either direction, which could shake the financial markets, as NVIDIA has contributed a third of the Nasdaq 100 index's gains this year.
Goldman Sachs strategy expert Scott Rubner stated on Tuesday, "Everyone is betting, and there are position warning signals. The bar is set high, and by high, I mean that we are expecting a significant impact."
Driven by the artificial intelligence boom, NVIDIA's market value has doubled in the past year, leading to a broader impact on the market. Traders are now preparing for more volatility as market tension is rising. NVIDIA closed down 4.4% on Tuesday, dragging other large stocks lower.
Related Articles

Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.
Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


